Breaking Barriers with Epigenetics in the Fight Against AMR
We are delighted to share that Mr. Saransh Chaudhary, President of Global Critical Care at Venus Remedies Ltd and CEO of Venus Medicine Research Centre, has authored a compelling article published in Hindustan Times E-Paper. This insightful piece, titled "Opening Frontiers with Epigenetics in Battle Against AMR," sheds light on how epigenetic mechanisms, like DNA methylation and non-coding RNA molecules, are shaping our understanding of bacterial resistance and antibiotic effectiveness.
In his article, Mr. Chaudhary explains that while genetic mutations and horizontal gene transfer are well-established drivers of antimicrobial resistance (AMR), the emerging role of epigenetics offers promising new perspectives. Epigenetics is "the study of heritable changes in gene expression that do not involve alterations to the underlying DNA sequence," impacting how bacteria adapt to antibiotics. Mr. Chaudhary emphasizes that understanding these mechanisms could open the door for targeted interventions to combat AMR more effectively.
A key focus of the article is how DNA methylation—the addition of methyl groups to bacterial DNA—can regulate genes involved in resistance, such as those controlling efflux pumps and biofilm formation. These adaptations enable bacteria to evade antibiotic treatments. The article suggests that targeting bacterial epigenetic regulators, such as DNA methyltransferases, could offer new therapeutic avenues. However, Mr. Chaudhary also highlights the challenges of balancing these interventions without disrupting essential bacterial functions.
We invite our shareholders and stakeholders to explore this thought-provoking article to gain deeper insights into how epigenetics could shape the future of antibiotic therapies and contribute to overcoming global healthcare challenges.
At Venus Remedies, we remain committed to addressing pressing global health challenges, including the growing threat of antimicrobial resistance (AMR). Through continuous research, innovation, and strategic collaborations, we are pioneering solutions that aim to improve patient outcomes and public health. Our efforts extend beyond drug development, encompassing diagnostics, preventive care, and sustainable healthcare practices. By exploring cutting-edge fields like epigenetics, we are unlocking new possibilities for combating AMR and reinforcing our mission to safeguard global health.
